|Articles|January 2, 2013

Pharmaceutical Technology

  • Pharmaceutical Technology-01-02-2013
  • Volume 37
  • Issue 1

Pharma Conversation & Community

A round up of news from across the web, including trends from social social media platforms.

HITTING THE HEADLINES

FDA Issues Draft Guidance on Electronic Submissions

FDA has issued a draft guidance, Guidance for Industry: Providing Submissions in Electronic Format—Summary Level Clinical Site Data for CDER's Inspection Planning, which is one in a series of documents intended to assist sponsors and applicants making certain regulatory submissions to FDA in electronic format.

PharmTech.com/ElectronicGuidance

US Supreme Court to Hear Pay-for-Delay Case

The US Supreme Court agreed to hear a case that will decide whether brand-name drug companies may pay generic drug-companies to delay introduction of lower-cost generic drugs. The Supreme Court is to review a federal appeals court ruling that upheld a "pay-for-delay" arrangement.

PharmTech.com/SupremeCourt

Ranbaxy Recalls Atorvastatin Due to Quality Issues

Ranbaxy Pharmaceuticals is recalling certain lots of its atorvastatin tablets because of possible contamination with small glass particles (less than 1 mm in size). Ranbaxy has ceased atorvastatin manufacturing until it has thoroughly investigated the problem.

PharmTech.com/RanbaxyRecall

INDUSTRY M&As

  • Valeant Pharmaceuticals International has completed its acquisition of Medicis Pharmaceutical.

  • Isochem has expanded its range of intermediates by acquiring the British fine-chemicals company, Wychem.

  • French contract manufacturing firm Synerlab has acquired lyophilization specialist company Lyofal.

  • Amgen has agreed to buy Icelandic-based Decode Genetics for $415 million in an all-cash transaction.

SEEKING INPUT

PharmTech is seeking reader input for a future feature on parenteral drug manufacturing. Send your questions and thoughts to the Community Manager, Stephanie Sutton, at ssutton@advanstar.com.

READERS THINK THAT...

Take part in our latest poll at: PharmTech.com/Polls

ON THE BLOG

"Real-time devices for continuous feeding processes were discussed at a seminar I recently attended."

Jennifer Markarian, PharmTech.com/RealTime

See more posts at blog.PharmTech.com

MOST TWEETED

  • Pharma companies using new analytical methods to ensure quality of medicine ht.ly/g0oIm

  • How to optimize continuous processing and make it work in pharmaceutical manufacturing is a crucial issue. ht.ly/g4AtD

Articles in this issue

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.